Vaxxas

Vaxxas is a clinical-stage biotechnology company pioneering the high-density microarray patch (HD-MAP) for needle-free vaccine delivery. The company's proprietary technology consists of an array of thousands of vaccine-coated microprojections that perforate the outer layers of the skin when applied with an applicator, enabling direct deposition of vaccines into the dense population of immune cells in the skin. By utilizing a dry-coating formulation, the HD-MAP platform significantly improves vaccine stability at higher temperatures, reducing reliance on complex cold-chain logistics. Vaxxas is focused on commercializing this platform for applications in infectious diseases and oncology, working through collaborations with global pharmaceutical partners, governments, and research organizations.